Navigation Links
Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Date:7/16/2008

tudies has been locked.

About VIAject(TM)

VIAject(TM) is an ultra rapid-acting injectable human insulin intended for meal-time use by patients with Type 1 or Type 2 diabetes. In Phase I and Phase II clinical trials, VIAject(TM) has been shown to have a more rapid onset of activity than those reported for the existing rapid-acting insulin analogs. As a result, VIAject(TM) may be safer, require a lower dose and promote weight loss when compared to currently marketed meal-time insulins. VIAject(TM) has been tested in two pivotal Phase III clinical trials, which compared the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) has been tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM) a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives
'/>"/>

SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
4. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
5. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
6. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
7. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
8. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
9. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
10. Sosei Announces Completion of Phase III Trial for NorLevo(R)
11. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...and, January 7 Circassia Ltd, a sp...rgy and critical care, today,announced that follo...with,its ToleroMune(R) anti-allergy technology, t...for a further phase II clinical trial in cat aller...ecruited 120 patients with confirmed,cat allergie...
(Date:1/6/2009)... The Michael J. Fox Fou...our industry research teams for pre-clinical resea...sease. , , The funding was awarded under the Fo...This program, first launched in 2006, supports and...research. TDI is part of MJFF,s focus on ,de-r...
(Date:1/6/2009)...e, January 6 , - ...boration Until,December 2011 , - Expansion...body,Discovery in Ophthalmology , - Revise...rgan,Sublicenses to a Third Party , Exon...d a reinforcement,of its existing drug discovery ...
(Date:1/3/2009)... , , ROSEMONT, Ill., Jan. 2 /PRNewswire-USN...growing technology providing an increasing number ...f back pain according to an article in the January... of Orthopaedic Surgeons ( http://www.jaaos.org/ )...s, additional technical developments will allow MR...
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Roche completes acquisition of ARIUS 7890 1Roche completes acquisition of ARIUS 7890 2Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 1Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 1Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 3Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 4World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 1World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 2
... - Journal Article Also Demonstrates the Promise o...ibiotics -, PALO ALTO, Calif., June 21, 2007 /PRNe...d pharmaceutical company, announced,today that the...that details how AN2690, the company,s lead clinic...th synthesis of a specific,protein required for fu...
... FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - N...ublication in the June 23 issue,of the journal The...ne therapy trial for Parkinson,s disease and the f...,s own brain cells for any adult,neurodegenerative... in 12 patients with,advanced Parkinson,s disease ...
Other Medicine Technology:Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 2Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:1/8/2009)...s are available that work, CDC officials stress ,...he most common strain of flu this season is resist...ernment health officials said Thursday there is no...n so far has been slow, and that other drugs work ... officials adopting a watchful attitude for now. ,...
(Date:1/8/2009)...May Be Revealed Friday, January 9 , , WASHINGT...ice Employees International Union (SEIU) President... International Executive Board to discuss the forc...mbers out of SEIU United Healthcare Workers-West (... final decision until tomorrow. , , According t...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
(Date:1/8/2009)...Jude Children,s Research Hospital have demonstrate...ia following influenza. They found that the antibi...teria by inhibiting their protein synthesis, are m... with the "beta-lactam" antibiotic ampicillin, whi...e finding is important because pneumonia, rather t...
Breaking Medicine News(10 mins):Health News:Common Flu Strain Resistant to Popular Antiviral Drug 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 3Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3
...sk of having a premature baby is up for women who ... cervix to eliminate precancerous cells, called LE...University revealed. After conducting a study in...hat nearly 1,500 premature births could have been ...
...ood - quick, convenient and cheap, which, we all k...ble cheeseburger costs less than a head of lettuce...es are one of the keys to good health; Barbara Rol...t encouraging people to eat large quantities of lo...
...rt published by the U.S. Centers for Disease Contr...is becoming widespread and aggressive among teenag...on pattern of excessive alcohol use" and the Natio...olism defines binge drinking as a pattern of drink...
...chers, in the first study of its kind, have comput...d found they are less prone to harm than collegiat...rs at Rhode Island Hospital and Brown Medical Scho...ished in the January 2007 issue of the American Jo...
Other Medicine News:Health News:Surfing Safer Than Soccer: Study 2Health News:Surfing Safer Than Soccer: Study 3
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: